amlodipine + valsartan + chlortalidone

Exone Plus is an oral fixed-dose triple combination therapy developed by HK inno.N for the management of hypertension. It combines three antihypertensive agents with complementary mechanisms of action: amlodipine, valsartan, and chlorthalidone. Amlodipine is a dihydropyridine calcium channel blocker (CCB) that inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle, leading to vasodilation and reduced peripheral vascular resistance. Valsartan is an angiotensin II receptor blocker (ARB) that selectively inhibits the binding of angiotensin II to the AT1 receptor, thereby blocking its vasoconstrictive and aldosterone-secreting effects. Chlorthalidone is a long-acting thiazide-like diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule of the nephron, promoting diuresis and reducing extracellular fluid volume. This triple combination is typically indicated for patients whose blood pressure is not sufficiently controlled by dual therapy (e.g., CCB/ARB combinations), offering improved convenience and potentially better adherence compared to taking the components separately.

Brand names

Exone Plus

Other names

Exone Plus Tab.